Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Glaukos' Epioxa therapy is proving its staying power. New three-year data show that a single treatment for keratoconus — a progressive eye disease that distorts vision — sustained meaningful improvements in both vision and corneal shape, with no serious adverse events reported. Nearly 30% of treated eyes gained two or more lines on a standard vision chart, and no patients needed additional intervention.
Glaukos' Epioxa therapy is proving its staying power. New three-year follow-up data show that a single treatment for keratoconus — a progressive eye disease that typically begins in adolescence or early adulthood and can eventually require a corneal transplant — sustained meaningful improvements in both vision and corneal shape. No patients required additional intervention during the entire follow-up period, and 92% of treated eyes completed the three-year assessment.
Epioxa stands out because it's less invasive than older approaches: it doesn't require removal of the cornea's outer protective layer before treatment. The safety profile also held up well, with no serious adverse events, treatment-related adverse events, or treatment discontinuations reported.
By the Numbers:
Why it matters: Long-term, single-dose efficacy is a big deal in a disease that can rob young patients of their vision over time. These results bolster Epioxa's case as a durable, minimally invasive option that could reduce the burden of repeat treatments and delay — or prevent — the need for corneal transplants.
